Development and assessment of a new cage-like particle adjuvant.

about

Genetic Engineering of Co-producing Antigen and the Mucosal Adjuvant 3' 5'- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype

P2860

Q58764447-983FD43F-6D2B-4551-A747-36643D35D67B

P2860

Development and assessment of a new cage-like particle adjuvant.

Item

http://www.wikidata.org/entity/Q40152711

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Development and assessment of a new cage-like particle adjuvant.

@en

type

Item

label

Development and assessment of a new cage-like particle adjuvant.

@en

prefLabel

Development and assessment of a new cage-like particle adjuvant.

@en

P1476

Development and assessment of a new cage-like particle adjuvant.

@en

P2093

Alcides Nicastro

http://www.w3.org/2001/XMLSchema#string

Daiana Bertona

http://www.w3.org/2001/XMLSchema#string

Gabriel Cabrera

http://www.w3.org/2001/XMLSchema#string

Iván Bontempi

http://www.w3.org/2001/XMLSchema#string

Iván Sergio Marcipar

http://www.w3.org/2001/XMLSchema#string

Luis Calvinho

http://www.w3.org/2001/XMLSchema#string

Luis Gugliotta

http://www.w3.org/2001/XMLSchema#string

Nazarena Pujato

http://www.w3.org/2001/XMLSchema#string

Verónica Gonzalez

http://www.w3.org/2001/XMLSchema#string

P2860

Local innate immune responses in the vaccine adjuvant-injected muscle

CD8+ T cells in Trypanosoma cruzi infection

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid.

Cage-like complexes formed by DOTAP, Quil-A and cholesterol.

Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms.

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.

Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.

On the preparation, microscopic investigation and application of ISCOMs.

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

P304

1293-1303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JPHP.12768

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Flavia Hozbor

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28664569

http://www.w3.org/2001/XMLSchema#string

Development and assessment of a new cage-like particle adjuvant.

about

P2860

P2860

Development and assessment of a new cage-like particle adjuvant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698